Skip to main content

Table 2 Changes in laboratory indices before and after treatment

From: Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis

Laboratory index

Group

Before treatment

1 week after treatment

1 month after treatment

F

P

WBC

(×109/L)

R

2.55 ± 2.21

5.45 ± 3.32

5.74 ± 2.52

8.896

0.002

C

4.29 ± 3.37

8.77 ± 4.69

9.62 ± 5.17

Fibrinogen

(g/L)

R

0.9 ± 0.35

1.65 ± 0.66

2.17 ± 0.89

86.247

<  0.001

C

1.36 ± 0.49

2.62 ± 0.21

3.94 ± 1.45

Ferritin (μg/L)

R

17,090 ± 17,586

828.1 ± 646.4

178.9 ± 166.1

22.493

<  0.001

C

12,579 ± 18,748

4765.6 ± 4562.2

597.6 ± 783.3

IL-2R(U/mL)

R

9381.3 ± 12,865.4

2540 ± 1381.5

494.2 ± 195.8

5.146

0.036

C

1784.5 ± 516.4

760 ± 155.6

390 ± 84.8

  1. WBC white blood cell; IL-2R interleukin-2 receptor; Group R ruxolitinib-treated group; Group C control group treated with conventional therapy. P-values describe comparisons within each group before and after treatment
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096